Immunoglobulin-resistant Kawasaki disease
Bibiana Marriaga-Núñez1, Araceli Arellano-Valdez2, Juan P Abarca-de la Paz3
1Hospital General de Zapopan, Secretaría de Salud, Unidad de Nosocomiales Hospital Arboledas, Guadalajara, Jalisco.
Background:
Kawasaki disease is a systemic vasculitis that affects small and medium-sized vessels, primarily the coronary arteries. First-line treatment includes intravenous immunoglobulin (IVIG) and acetylsalicylic acid; however, 20% do not respond adequately despite treatment. We describe a case treated with etanercept after initial IVIG failure, showing a good response.
Case Report:
A 5-year-old female was diagnosed with classic Kawasaki disease. Echocardiography and angiotomography revealed giant and fusiform aneurysms in the coronary arteries. A first dose of IVIG therapy was administered without improvement; after the second dose, the fever persisted, so etanercept was administered, and the fever subsided. There were no new lesions in medium-caliber vessels and the previously identified coronary lesions did not progress.
Conclusions:
The use of etanercept in Kawasaki disease has demonstrated a clinically favorable response. Controlled clinical trials of this drug are needed to establish it as a formal therapy in cases of initial IVIG failure.
Related Concept Videos
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Rheumatic Heart Disease I: Introduction


